Adverse Event reporting information can be found in footer

Request a Meeting
PI
Home A Different Class of ADT Control CV Risk Economic Burden of CVD Events Disease-Related Symptoms Delay Disease Progression Patient Satisfaction Support & Resources Dosing & Administration Firmagon Licence Prescribing Information
Firmagon degarelix. Think beyond the prostate Icon Icon Icon Icon

FIRMAGON® licence and indication

How many of your patients could benefit from FIRMAGON®s extended licence?
Learn More...

FIRMAGON® extended licence

FIRMAGON® is still the only GnRH antagonist approved before or after radiotherapy for patients with high-risk localised or locally advanced hormone-dependent prostate cancer.1-3

Localised prostate cancer
Locally advanced PCa
Metastatic PCa
Low Risk
Intermediate Risk
High Risk
PSA <10 ng/mL
PSA 10-20 ng/mL
PSA >20 ng/mL
Any PSA
Any PSA
+ Gleason score <7
OR Gleason score =7
OR Gleason score >7
Any Gleason score
Any Gleason score
cT1-2a
OR T2b
OR T2c
T3-4 or N1
T3/4, N1, M1
FIRMAGON® extended licence
FIRMAGON® initial licence

Adapted from European Association of Urology Guidelines, 20224

FIRMAGON® is indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer, also in combination with radiotherapy and as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally hormone-dependent dependent prostate cancer.1,2

up arrow dark up arrow down arrow dark down arrow
▲ SECTION NAVIGATION ▲